Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySummaCare Deep Brain Stimulation Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Deep Brain Stimulation Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity for deep brain stimulation (DBS), including electrode implantation, pulse generators, and related components, for Commercial and Medicare members. It identifies covered indications, clinical criteria, exclusions, and experimental or unproven uses.

    Policy Summary
    PayerSummaCare
    PolicyDeep Brain Stimulation Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 13, 2026
    Next Review DateN/A
    Key ActionFor Commercial members, submit documentation showing that the requested DBS target and indication meet the applicable medical-necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Plan segments covered
    3Commercial indication groups

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Medicare target groups
    3 monthsMedication-management trial
    30 pointsMinimum off-medication UPDRS score
    27Experimental or investigational indications listed

    Coverage Criteria

    Commercial Thalamic DBS

    Covered when the member has a drug-unresponsive condition listed below.

    ONE of the following conditions

    • Essential tremor unresponsive to drug therapy.
    • Parkinson's disease unresponsive to drug therapy.

    Commercial STN or GPi DBS

    Covered when the applicable condition-specific criteria are met.

    ONE of the following condition pathways

    • Intractable dystonia

      • Member is age 7 years or older.
      • Member has intractable dystonia, including generalized, segmental, cervical dystonia, or hemidystonia.
      • The dystonia is adequately controlled after a 3-month trial of medication management.
    • Parkinson's disease

      • Member has Parkinson's disease.
      • Good response to levodopa.
      • Motor complications are unresponsive to medication management.
      • Motor portion of the United Parkinson's Disease Rating Scale is at least 30 points when off medication for 12 hours.>= 30 points
    • Essential or disabling tremor

      • Member has essential tremor or a disabling tremor causing limitations in activities of daily living.
      • Tremor is unresponsive to a 3-month trial of medication management.

    Commercial Anterior Thalamic DBS

    Covered when all of the following criteria are met.

    ALL of the following

    • Member is an adult age 18 years or older.>= 18 years
    • Member has partial-onset seizures.
    • Seizures are unresponsive to a 3-month trial of medical management.

    Medicare CMS NCD 160.24 Covered Indications

    Medicare covers the listed DBS procedures only when all applicable requirements are met.

    General Medicare requirements and one covered target pathway

    • The DBS device is FDA-approved for DBS, or the device is used in accordance with FDA-approved protocols governing Category B Investigational Device Exemption (IDE) DBS clinical trials.
    • ONE covered target pathway

      • Thalamic VIM DBS for essential tremor or tremor-dominant idiopathic Parkinson's disease

        • Diagnosis

          • Essential tremor based on postural or kinetic tremors of the hands without other neurologic signs.
          • Idiopathic Parkinson's disease in a tremor-dominant form, with at least 2 cardinal features: tremor, rigidity, or bradykinesia.

    DBS is not reasonable and necessary and is not covered for essential tremor or Parkinson's disease patients with any of the following: non-idiopathic Parkinson's disease or Parkinson's Plus syndromes; cognitive impairment, dementia, or depression that would be worsened by or interfere with the patient's ability to benefit from DBS; current psychosis, alcohol abuse, or other drug abuse; structural lesions such as basal ganglionic stroke, tumor, or vascular malformation as the etiology of the movement disorder; previous movement-disorder surgery within the affected basal ganglion; or significant medical, surgical, neurologic, or orthopedic comorbidities that contraindicate DBS surgery or stimulation.

    Deep brain stimulation and cortical stimulation for treating obsessive-compulsive disorder (OCD) and all other indications not listed above are unproven and not medically necessary due to insufficient evidence of efficacy. Responsive cortical stimulation for all other indications not listed above is also unproven and not medically necessary.

    SummaCare considers DBS for tremors caused by trauma, multiple sclerosis, degenerative disorders, metabolic disorders, infectious diseases, or drug-induced movement disorders experimental and investigational.

    SummaCare considers DBS experimental and investigational for the following indications, including but not limited to, because there is insufficient evidence to support effectiveness: addiction; Alzheimer's disease; anorexia nervosa; autism spectrum disorder; blepharospasm; cerebral palsy; chronic cluster headache; chronic pain syndrome, including complex regional pain syndrome/reflex sympathetic dystrophy; chronic vegetative state; dementia; depression; disorders of consciousness, including minimally conscious state, unresponsive wakefulness syndrome, and vegetative state; explosive aggressive behavior; head or voice tremor; Huntington's disease; obesity; obsessive-compulsive disorder; orthostatic tremor; Parkinson's disease-related camptocormia, dysarthria or speech deficits, postural instability, restless legs syndrome, and gait disorders such as gait instability and freezing of gait; posttraumatic tremor; Parkinson's disease stage V; postural trunk deformities; self-injurious behavior; substance use disorders; tinnitus; Tourette syndrome; and traumatic brain injury.

    Coding and Clinical Thresholds

    CPT CodesCPT
    61850Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical
    61860Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral, cortical
    61863Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; first array
    61864Each additional array (List separately in addition to primary procedure)
    61867Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; first array
    61868Each additional array (List separately in addition to primary procedure)
    61880Revision or removal of intracranial neurostimulator electrodes
    61885Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array
    61886with connection to 2 or more electrode arrays
    61888Revision or removal of cranial neurostimulator pulse generator or receiver
    HCPCS CodesHCPCS
    L8679Implantable neurostimulator, pulse generator, any type
    L8680Implantable neurostimulator electrode, each
    L8682Implantable neurostimulator radiofrequency receiver
    L8685Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
    L8686Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension
    L8687Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
    L8688Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension
    Medication-management trial
    Required duration3 months of medication management
    Off-medication UPDRS motor score
    Minimum UPDRS motor score30 points
    Medication washout12 hours off medication
    Fahn-Tolosa-Marin Clinical Tremor Rating Scale
    Required severityLevel 3 or 4 on the Fahn-Tolosa-Marin Clinical Tremor Rating Scale

    Authorization and Denial Considerations

    Documentation Required

    Commercial Medical-Necessity Documentation

    For commercial members, document the requested DBS target, diagnosis, severity, prior treatment response, and functional impact to establish that the indication meets SummaCare medical-necessity criteria.

    • Identify the target: unilateral thalamic DBS for essential tremor or Parkinson’s disease; subthalamic nucleus or globus pallidus DBS for qualifying dystonia, Parkinson’s disease, or essential/disabling tremor; or bilateral anterior thalamic DBS for qualifying adults with partial-onset seizures.
    • For dystonia, document age 7 years or older, intractable generalized, segmental, cervical dystonia, or hemidystonia, and adequate control after a 3-month medication-management trial.
    • For Parkinson’s disease, document good levodopa response, motor complications unresponsive to medication management, and a minimum off-medication UPDRS motor score of 30.
    • For essential or disabling tremor, document limitations in activities of daily living and failure of a 3-month medication-management trial. For partial-onset seizures, document age 18 years or older and failure of a 3-month trial of medical management.

    Deep Brain Stimulation Overview

    Deep brain stimulation (DBS) is an elective neurosurgical procedure that implants electrodes in targeted brain regions to deliver programmable electrical impulses intended to regulate abnormal brain activity. The system includes an intracranial electrode or lead, an extension wire, and a programmable implantable pulse generator generally placed beneath the skin of the upper chest. The procedure is addressed when medication therapy is ineffective or insufficient to maintain function or quality of life.

    Defined Terms

    Deep brain stimulation
    SystemAn implanted system that uses electrodes, extension wiring, and a programmable pulse generator to deliver electrical stimulation to selected brain areas
    Electrode or leadThin, insulated wire implanted into a specific brain area through a small opening in the skull
    Extension wireInsulated wire passed under the skin of the head, neck, and shoulder to connect the electrode to the internal pulse generator
    Implantable pulse generatorProgrammable generator placed under the skin, usually in the upper chest, to control stimulation
    Electrode or lead
    DefinitionA thin, insulated wire inserted through a small opening in the skull and implanted into a specific brain area
    Policy Summary
    PayerSummaCare
    PolicyDeep Brain Stimulation Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 13, 2026
    Next Review DateN/A
    Key ActionFor Commercial members, submit documentation showing that the requested DBS target and indication meet the applicable medical-necessity criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Denial ConsiderationsDeep Brain Stimulation OverviewDefined Terms
  1. Marked disabling tremor in the extremity intended for treatment, rated at least level 3 or 4 on the Fahn-Tolosa-Marin Clinical Tremor Rating Scale or an equivalent scale, causing significant limitation in daily activities despite optimal medical therapy.Level 3 or 4 or equivalent
  2. Willingness and ability to cooperate during the conscious operative procedure and during post-surgical evaluations, medication adjustments, and stimulator-setting adjustments.

    Applies to unilateral or bilateral thalamic ventralis intermedius nucleus (VIM) DBS.

  3. STN or GPi DBS for Parkinson's disease

    • Diagnosis of Parkinson's disease based on at least 2 cardinal features: tremor, rigidity, or bradykinesia.
    • Advanced idiopathic Parkinson's disease as determined using Hoehn and Yahr stage or the Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor subscale.
    • L-dopa responsive disease with clearly defined on periods.
    • Persistent disabling Parkinson's symptoms or drug side effects, such as dyskinesias, motor fluctuations, or disabling off periods, despite optimal medical therapy.
    • Willingness and ability to cooperate during the conscious operative procedure and during post-surgical evaluations, medication adjustments, and stimulator-setting adjustments.

      Applies to unilateral or bilateral subthalamic nucleus (STN) or globus pallidus interna (GPi) DBS.

  4. Equivalent measure
    An equivalent scale may be used
    Minimum age for dystonia
    Minimum age7 years or older
    Applicable indicationIntractable dystonia
    Minimum age for anterior thalamic stimulation
    Minimum age18 years or older
    Applicable indicationPartial-onset seizures treated with bilateral anterior-nucleus thalamic stimulation
    Prior Authorization

    Medicare NCD 160.24 Criteria

    For Medicare, authorization must demonstrate compliance with CMS NCD 160.24. Coverage is limited to specified DBS targets and essential tremor or Parkinson’s disease indications when all applicable clinical criteria are met.

    • The device must be FDA approved for DBS or used under an FDA-approved protocol for a Category B Investigational Device Exemption DBS clinical trial.
    • For VIM DBS, document essential tremor with postural or kinetic hand tremor and no other neurologic signs, or tremor-dominant idiopathic Parkinson’s disease with at least two cardinal features; disabling tremor at Fahn-Tolosa-Marin level 3 or 4 (or equivalent) despite optimal medical therapy; and willingness and ability to cooperate during surgery and follow-up programming.
    • For STN or GPi DBS, document idiopathic Parkinson’s disease with at least two cardinal features; advanced disease by Hoehn and Yahr stage or UPDRS part III; levodopa responsiveness with defined on periods; persistent disabling symptoms or medication side effects despite optimal therapy; and willingness and ability to cooperate during surgery and follow-up programming.
    Denial Risk

    Commercial Criteria Not Met

    Commercial coverage may be denied when the requested indication, target, clinical severity, treatment response, or required medication-management trial is not documented or does not satisfy SummaCare criteria.

    • The requested DBS target or indication is not one of the covered commercial indications.
    • The member does not meet the applicable age, diagnosis, severity, functional-impact, medication-response, or treatment-failure requirements.
    • Required documentation is absent, including good levodopa response and qualifying UPDRS score for Parkinson’s disease, or the required medication-management trial for dystonia, tremor, or seizures.
    Denial Risk

    Medicare Criteria and Exclusions

    Medicare DBS claims may be denied when the device or clinical indication does not satisfy CMS NCD 160.24, or when an applicable exclusion makes DBS not reasonable and necessary.

    • The device is neither FDA approved for DBS nor used under an FDA-approved Category B IDE DBS protocol.
    • The patient fails any applicable VIM, STN, or GPi clinical criterion, including diagnosis, tremor severity, disease stage, levodopa responsiveness, persistent disabling symptoms, or ability to cooperate with surgery and follow-up.
    • DBS is not covered for non-idiopathic or Parkinson’s Plus syndromes; cognitive impairment, dementia, or depression that would be worsened by or interfere with benefit; current psychosis or alcohol or drug abuse; structural lesions causing the movement disorder; prior movement-disorder surgery in the affected basal ganglion; or significant contraindicating medical, surgical, neurologic, or orthopedic comorbidities.
    Denial Risk

    Unlisted or Investigational Indication

    DBS for indications outside the listed covered criteria should be treated as unproven, experimental, investigational, or not medically necessary unless applicable evidence and coverage requirements establish otherwise. Providers should not assume authorization based solely on a diagnosis or on a request for a different DBS target.

    • SummaCare considers DBS or cortical stimulation for OCD and other unlisted indications unproven and not medically necessary; DBS for tremors caused by trauma, multiple sclerosis, degenerative, metabolic, infectious, or drug-induced disorders is experimental and investigational.
    • Examples of experimental or investigational indications include addiction, Alzheimer’s disease, autism spectrum disorder, blepharospasm, cerebral palsy, chronic cluster headache, chronic pain, dementia, depression, Huntington’s disease, obesity, Tourette syndrome, traumatic brain injury, and other indications listed in the policy.
    • Parkinson’s-related camptocormia, dysarthria or speech deficits, postural instability, restless legs syndrome, gait disorders, and stage V Parkinson’s disease are also identified as experimental and investigational.
    Extension wire
    DefinitionAn insulated wire passed under the skin of the head, neck, and shoulder that connects the electrode to the internal pulse generator
    Implantable pulse generator
    DefinitionThe programmable device that controls stimulation and is usually implanted under the skin in the upper chest